SG11201900214UA - Iso-citrate dehydrogenase (idh) inhibitor - Google Patents

Iso-citrate dehydrogenase (idh) inhibitor

Info

Publication number
SG11201900214UA
SG11201900214UA SG11201900214UA SG11201900214UA SG11201900214UA SG 11201900214U A SG11201900214U A SG 11201900214UA SG 11201900214U A SG11201900214U A SG 11201900214UA SG 11201900214U A SG11201900214U A SG 11201900214UA SG 11201900214U A SG11201900214U A SG 11201900214UA
Authority
SG
Singapore
Prior art keywords
international
shanghai
idh
pct
building
Prior art date
Application number
SG11201900214UA
Inventor
Jibin Yang
Original Assignee
Shanghai Meton Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Meton Pharmaceutical Co Ltd filed Critical Shanghai Meton Pharmaceutical Co Ltd
Publication of SG11201900214UA publication Critical patent/SG11201900214UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111111111 11111111111111111111110111111 001111111111011110111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/010637 Al 18 January 2018 (18.01.2018) W I P0 I P C T (51) International Patent Classification: C07D 417/14 (2006.01) A61P 31/04 (2006.01) A61K 31/4436 (2006.01) (21) International Application Number: PCT/CN2017/092506 (22) International Filing Date: 11 July 2017 (11.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/CN2016/090022 14 July 2016 (14.07.2016) CN (71) Applicant: SHANGHAI METON PHARMACEUTI- CAL CO., LTD [CN/CN]; Room 3106, Building 3, No.1399 Zhangheng Road, Pilot Free Trade Zone, Shanghai 201203 (CN). (72) Inventor: YANG, Jibin; Suite 702, Building 43, Area 7, Lane 1467, Caobao Road, Shanghai 201101 (CN). Agent: JUN HE LAW OFFICES; 20/F, China Resources (74) Building, 8 Jianguomenbei Avenue, Beijing 100005 (CN). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (84) ,— I Published: ..! — with international search report (Art. 21(3)) N N r) M 0 1 1 O_ 0 (54) Title: ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR 1-1 0 (57) : Disclosed are compounds inhibiting the conversion of a—KG to D-2 -HG, pharmaceutically acceptable salts, hydrates, ei solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compounds and pharmaceutical 0 compositions can effectively treat IDH associated diseases, including cancer.
SG11201900214UA 2016-07-14 2017-07-11 Iso-citrate dehydrogenase (idh) inhibitor SG11201900214UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2016/090022 WO2018010142A1 (en) 2016-07-14 2016-07-14 Iso-citrate dehydrogenase (idh) inhibitor
PCT/CN2017/092506 WO2018010637A1 (en) 2016-07-14 2017-07-11 Iso-citrate dehydrogenase (idh) inhibitor

Publications (1)

Publication Number Publication Date
SG11201900214UA true SG11201900214UA (en) 2019-02-27

Family

ID=60952234

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900214UA SG11201900214UA (en) 2016-07-14 2017-07-11 Iso-citrate dehydrogenase (idh) inhibitor

Country Status (7)

Country Link
US (1) US10752626B2 (en)
EP (1) EP3484882B1 (en)
JP (1) JP7021405B2 (en)
CN (1) CN109641890B (en)
CA (1) CA3030458C (en)
SG (1) SG11201900214UA (en)
WO (2) WO2018010142A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019296173B2 (en) * 2018-06-26 2022-01-06 Kpc Pharmaceuticals, Inc. Benzimidazole derivatives and use thereof as IDH1 inhibitors
MA53430A (en) * 2018-08-24 2021-06-30 Xeniopro GmbH NEW COMPOUNDS
CN114555597A (en) * 2019-10-12 2022-05-27 浙江迈同生物医药有限公司 Isocitrate Dehydrogenase (IDH) inhibitors
CA3226162A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
WO2023051635A1 (en) * 2021-09-28 2023-04-06 上海艾力斯医药科技股份有限公司 Fused ring compound, and preparation method therefor and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
US7837251B2 (en) * 2007-09-19 2010-11-23 Honda Motor Co., Ltd. Rear-quarter window appearance
WO2009072581A1 (en) * 2007-12-05 2009-06-11 Aska Pharmaceutical Co., Ltd. Lactam compound or salt thereof, and ppar activator
GB0909671D0 (en) * 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2015006591A1 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
US10245266B2 (en) * 2014-05-19 2019-04-02 Celgene Corporation 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
AU2015324158A1 (en) * 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
AU2015325279B2 (en) * 2014-10-01 2020-02-27 Daiichi Sankyo Company, Limited Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor
JP2017533727A (en) * 2014-10-13 2017-11-16 セルジーン コーポレイション Methods of treating solid tumors and use of biomarkers as predictors of clinical sensitivity to immunomodulatory therapy
DK3214081T3 (en) * 2014-10-30 2020-09-28 Kangpu Biopharmaceuticals Inc ISOINDOLIN DERIVATIVE, INTERMEDIATE PRODUCT, METHOD OF MANUFACTURE, PHARMACEUTICAL COMPOSITION AND USE
WO2016105518A1 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Also Published As

Publication number Publication date
CA3030458A1 (en) 2018-01-18
CA3030458C (en) 2024-02-13
US20190256511A1 (en) 2019-08-22
CN109641890B (en) 2022-04-26
WO2018010142A1 (en) 2018-01-18
WO2018010637A1 (en) 2018-01-18
US10752626B2 (en) 2020-08-25
EP3484882A4 (en) 2020-02-26
JP2019522056A (en) 2019-08-08
EP3484882A1 (en) 2019-05-22
JP7021405B2 (en) 2022-02-17
EP3484882B1 (en) 2022-04-27
CN109641890A (en) 2019-04-16

Similar Documents

Publication Publication Date Title
SG11201809714TA (en) Piperidines as menin inhibitors
SG11201909325RA (en) 2-amino-quinoline derivatives
SG11201900135YA (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201804915RA (en) Methods for treating huntington's disease
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201907023UA (en) Method of reducing neutropenia
SG11201900214UA (en) Iso-citrate dehydrogenase (idh) inhibitor
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201808990QA (en) Compositions for topical application of compounds
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists